Big Moving Stock keep track of the biggest moving stocks in the market.


Nasdaq: GOOG NFLX BIIB AMZN IBB TSLA WYNN ILMN ALXN CHTR Z SLXP AMGN GMCR COST PCYC FFIV WDC SSYS
Nyse: ACT PXD V LNKD MCK IVV IBM GS SPG LMT AGN FDX TWC WHR MMM CMI XEC CXO APD CVX
New Highs: EXPE BYI CYH SPR X IDIX SCI

The Hot Industries

Biotechnology 1
Personal Services 1
Steel & Iron 1

The Hot Sectors

Services 3
Healthcare 1
Industrial Goods 1

SPPI Stock Chart


SPPI
Analyze

Sector:

Healthcare
Daily

Industry:

Biotechnology
Weekly

Employees:

N/A
Monthly

Website:

http://www.sppirx.com

SPPI Spectrum Pharmaceuticals, Inc.

Spectrum Pharmaceuticals, Inc., a biotechnology company, develops and commercializes oncology and hematology drug products. The company’s commercialized drug products include FUSILEV for the treatment of patients with metastatic colorectal cancer, rescue after high-dose methotrexate therapy in osteosarcoma, and to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma; ZEVALIN injection for intravenous use as a prescription medication; and MARQIBO, a sphingomyelin/cholesterol liposome-encapsulated formulation of the anticancer drug vincristine for the treatment of adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia. It also develops BELEODAQ for the treatment of various hematological and solid tumors; Captisol-enabled MELPHALAN, an intravenous formulation of MELPHALAN for clinicians and patients in the multiple myeloma transplant setting; APAZIQUONE to treat non-muscle invasive bladder cancer; and SPI-2012 for the treatment of chemotherapy-induced neutropenia. The company sells its drugs through a direct sales force in the United States; and through distributors in Europe and Japan. It has licensing and development agreement with Cell Therapeutics, Inc.; license agreement with Merck & Cie AG and Cydex Pharmaceuticals, Inc.; development and commercialization collaboration agreement with Allergan; collaboration agreement with Nippon Kayaku Co., Ltd.; licensing and collaboration agreement with TopoTarget A/S; and co-development and commercialization agreement with Hanmi Pharmaceutical Company. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Henderson, Nevada.

favicon

Biotech Stocks Scanner -- Regeneron Pharma, BioCryst Pharma, Spectrum Pharma, Exact Sciences, and Vical Inc.

21 Jul 2014, 7:27 amLONDON, July 21, 2014 /PRNewswire/ -- On Friday, July 18, 2014, the NASDAQ Composite ended at 4,432.15, up 1.57%, the Dow Jones Industrial Average finished the day 0.73% higher at 17,100.18, and the S&P 500 closed at 1,978.22, up 1.03%. The gains were broad based as all the sectors...
favicon

UPDATE: BTIG Initiates Coverage On Masimo, Sees 31% Premium To Shares

8 Jul 2014, 10:36 amBTIG analyst Sean Lavin initiated coverage on Masimo (NASDAQ: MASI ) with a Buy rating and $32.00 price target. Lavin is optimistic on the medical technology company's future, seeing limited downside for ...
favicon

Spectrum Pharmaceuticals Gains U.S. Approval of Beleodaq - Analyst Blog

7 Jul 2014, 2:59 pmSpectrum Pharmaceuticals Gains U.S. Approval of Beleodaq - Analyst Blog
favicon

Why Spectrum Pharmaceuticals (SPPI) Stock Is Higher This Morning

7 Jul 2014, 8:36 amNEW YORK (TheStreet) -- Shares of Spectrum Pharmaceuticals, Inc. are up 1.69% to $9.05 after the biotech company announced that the FDA granted Accelerated Approval of Beleodaq for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be ...
favicon

Spectrum Pharmaceuticals Shares Up 5% Following FDA Accelerated Approval For Beleodaq (SPPI)

3 Jul 2014, 9:46 amShares of Spectrum Pharmaceuticals (NASDAQ: SPPI ) gained 5.7 percent following the U.S. Food and Drug Administration's approval of the New Drug Application (NDA) for Beleodaq. Accelerated Approval for ...